Breast cancer subtypes and outcome after local and regional relapse

Annals of Oncology

Volumn 23, Issue 2, 2012, Pages 324-331

  Montagna, E ^a   Bagnardi, V ^a,b,c   Rotmensz, N ^a   Viale, G ^a,d   Renne, G ^a,d   Cancello, G ^a   Balduzzi, A ^a   Scarano, E ^a   Veronesi, P ^a,d   Luini, A ^a   Zurrida, S ^a,d   Monti, S ^a   Mastropasqua, M G ^a   Bottiglieri, L ^a   Goldhirsch, A ^a   Colleoni, M ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c Frontier Science and Technology Research Foundation Southern Europe   (Switzerland)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Breast; Cancer; Locoregional; Relapse

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CANCER SURGERY; CONTROLLED STUDY; DEATH; ELECTRON THERAPY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOCOREGIONAL RECURRENCE; MAJOR CLINICAL STUDY; MALE; METASTASIS; OUTCOME ASSESSMENT; PATIENT INFORMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84856335984     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr129     Document Type: Article

References (27)

1. Fisher B, Anderson S, Bryant J et al. Twenty year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; 347: 1233-1241.
2. Veronesi U, Cascinelli N, Mariani L et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002; 347: 1227-1232.
3. Blichert-Toft M, Nielsen M, Dü ring M et al. Long-term results of breast conserving surgery vs. mastectomy for early stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG-82TM protocol. Acta Oncol 2008; 47(4): 672-681.
4. Valagussa P, Tess JD, Rossi A et al. Adjuvant CMF effect on site of first recurrence, and appropriate follow-up intervals, in operable breast cancer with positive axillary nodes. Breast Cancer Res Treat 1981 1: 349-356.
5. Goldhirsch A, Gelber RD, Price KN et al. Effect of systemic adjuvant treatment on first site of breast cancer relapse. Lancet 1994; 343: 377-381.
6. Whelan T, Clark R, Roberts R et al. Ipsilateral breast tumor recurrence postlumpectomy is predictive of subsequent mortality: results from a randomized trial. Int J Radiat Oncol Biol Phys 1994; 30: 11-16.
7. Kamby K, Senegelov L. Pattern of dissemination and survival following isolated locoregional recurrence of breast cancer: a prospective study with more than 10 years of followup. Breast Cancer Res Treat 1997; 45: 181-192.
8. Wapnir IL, Anderson SJ, Mamounas EP et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol 2006; 24: 2028-2037.
9. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumors. Nature 2000; 406(6797): 747-752.
10. de Ronde JJ, Hannemann J, Halfwerk H et al. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat 2010; 119(1): 119-126.
11. Cheang MC, Chia SK, Voduc D et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101(10): 736-750.
12. Hugh J, Hanson J, Cheang MC et al. Breast cancer subtypes and response to docetaxel in node positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009; 27: 1168-1176.
13. Colleoni M, Cole BF, Viale G et al. Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Clin Oncol 2010; 28(18): 2966-2973.
14. Colleoni M, Orvieto E, Nole' F et al. Prediction of response to primary chemotherapy for operable breast cancer. Eur J Cancer 1999; 35: 574-579.
15. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. Hoboken, NJ: Wiley & Sons Ltd 1980.
16. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-1154.
17. Cox D. R: regression models and life tables (with discussion). J R Stat Soc 1972; B34: 187-220.
18. Lee SH, Chung MA, Quddus MR et al. The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression and hormone receptor status in breast cancer. Am J Surg 2003; 186(4): 348-350.
19. Lower EE, Glass E, Blau R et al. HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 2009; 113: 301-306.
20. Wilking U, Skoog L, Elmberger G et al. HER2 gene amplification (HER2) and hormone receptor expression (ER/PR) in early (EBC) and metastatic breast cancer (MBC) in the same patients. J Clin Oncol 2007; 25 (18 Suppl): Abstract 1023.
21. Guarneri V, Giovannelli S, Ficarra G et al. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. Oncologist 2008; 13: 838-844.
22. CarreñO G, Del Casar JM, Corte MD et al. Local recurrence after mastectomy for breast cancer: analysis of clinicopathological, biological and prognostic characteristics. Breast Cancer Res Treat 2007; 102: 61-73.
23. Moran MS, Haffy BG. Loco-regional breast cancer recurrence: prognostic groups based on patterns of failure. Breast J 2002; 8: 81-87.
24. Colleoni M, O'Neill A, Goldhirsch A et al. Identifying breast cancer patients at high risk for bone metastases. J Clin Oncol 2000; 18(23): 3925-3935.
25. Nemoto R, Uchida K, Tsutsumi M et al. A model of localized osteolysis induced by the MBT-2 tumor in mice and its responsiveness to etidronate disodium. J Cancer Res Clin Oncol 1987; 113: 539-543.
26. Gnant M, Mlineritsch B, Schippinger W et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009 360(7): 679-691.
27. Waeber M, Castiglione-Gertsch M, Dietrich D et al. Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation. Ann Oncol 2003; 14: 1215-1221.